Early research (Phase 1)Study completedNCT02122861
What this trial is testing
Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1
Who this might be right for
Melanoma - Currently EnrollingNon-small Cell Lung Cancer - Enrollment CompletedSarcoma - Enrollment Completed
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 47